The company has total assets of 1.3 billion yuan and 551 employees. It has a subsidiary API factory and a plastic packaging branch, controls Hubei Dongsheng Pharmaceutical Co., Ltd., and participates in Xinjiang Xintei National Pharmaceutical Co., Ltd. The company has domestic leading modern factory facilities and superior production conditions. Its products are widely used in the medical field for their anti-viral, anti-bacterial, anti-inflammatory, anti-allergic and health-care properties. The company has always regarded seizing the commanding heights of science and technology as the basis for business development. In order to ensure that the technology is forward-looking, it attaches great importance to investment in research and development and strengthens technological innovation and new product development. The company has a R&D center with strong technical strength, a Qianjiang Pharmaceutical postdoctoral research station, and a fast-running, virtuous cycle scientific and technological innovation system from research to development and production. The company is committed to aiming at the forefront of international medical technology, launching 3-4 new drugs every year, and has now obtained new drug certificates for 23 new drugs, and has formed serial and large-scale production of many products. The company implements a 4C marketing model that puts customers first, and gradually formed it. It has passed GMP certification as a whole. It currently mainly produces and operates seven major dosage forms, including eye drops, injections, freeze-dried agents, tablets, capsules, granules, and chemical raw materials. 150 The high-quality and efficient marketing work system for multiple varieties, while vigorously promoting the office responsibility system, regional agency system, and drug bidding system, have achieved good results, and the product market share has been rising steadily.

The company's flagship product "Jing" brand eye drops series products rank first in the country in terms of production, sales and market share in the same industry; acyclovir series products, sodium cromoglycate raw materials and their series The product's production and sales volume are among the best in the same industry nationwide; Azithromycin granules, as the latest antibacterial and anti-inflammatory drug, were the first to be developed and launched in the country and won the Hubei Province Industrial Quality Brand Gold Award; the new product Ruizhu Eye Drops, a one-time small-dose preservative-free product, has reached international Advanced level, won the national key new product certificate and the title of consumer satisfaction product in Hubei Province. Levofloxacin Hydrochloride Ophthalmic Gel has filled the domestic gap; the "Jing" trademark and "Gantai" trademark have been rated as famous trademarks in Hubei Province.

In order to improve the company's comprehensive strength, the company's two major industrial parks (Yang City Biomedicine Industrial Park and Wuhan Zhuankou R&D Center) have been put into production and have devoted themselves to the pharmaceutical business field, marking the company's entry into the biopharmaceutical field. and the implementation of diversified operations have entered a new stage of development. The company will continue to carry forward the enterprise spirit of "unity, pragmatism, excellence and innovation", continue to maintain the many unique advantages of ophthalmic drugs, high-tech and listed companies, focus on the development of pharmaceutical preparations, with ophthalmic drugs as the main feature, and with Based on expanding the production scale of raw materials, taking antiviral, antibacterial drugs, biopharmaceuticals and modernization of traditional Chinese medicine as the development direction, adhering to the concept of "becoming bigger, better and stronger in the professional field", we are committed to integrating the production and operation management system with international standards. Comprehensively integrate and build the company into Asia's largest and world-renowned ophthalmic drug manufacturer.